United Kingdom

People: Allogene Therapeutics Inc (ALLO.OQ)

ALLO.OQ on NASDAQ Stock Exchange Global Select Market

13 Sep 2019
Change (% chg)

$-0.20 (-0.66%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Belldegrun, Arie 

Dr. Arie S. Belldegrun, M.D., FACS, serves as Executive Chairman of the Board, Co-Founder of the Company. He is a co-founder of Allogene and has served as Executive Chairman of our board of directors since November 2017. From March 2014 until October 2017 Dr. Belldegrun served as the President and Chief Executive Officer of Kite and as a director from June 2009 until October 2017. Dr. Belldegrun currently serves as Chairman of Urogen Pharma, Ltd., a position he has held since December 2012, as Chairman and Partner of Two River Consulting, LLC, a position he has held since June 2009, and as Chairman of the Board of Directors of Kronos Bio, Inc., a position that he has held since June 2017. Dr. Belldegrun has also served as Senior Managing Director of Vida Ventures, LLC since November 2017. Dr. Belldegrun previously served as a director of Teva Pharmaceutical Industries Ltd. from March 2013 until January 2017, Chairman of Arno Therapeutics, Inc. from March 2008 until January 2017, a director of Capricor Therapeutics, Inc. from September 2009 until November 2013, and a director of SonaCare Medical, LLC from October 2009 until October 2014. In 1996, he founded Agensys, Inc., a biotechnology company, where he served as its founding Chairman from 1996 to 2001, and continued to serve on the board until 2007 when it was acquired by Astellas Pharma Inc. Dr. Belldegrun was also the Founding Vice-Chairman of the board of directors and Chairman of the scientific advisory board of Cougar Biotechnology, Inc., a biotechnology company, from 2003 to 2009, when it was acquired by Johnson & Johnson. He is certified by the American Board of Urology and is a Fellow of the American College of Surgeons and the American Association of Genitourinary Surgeons. Dr. Belldegrun is Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and Director of the Institute of Urologic Oncology at the David Geffen School of Medicine at the University of California, Los Angeles, or UCLA.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD 8,226,850
Long-Term Incentive Plans, USD --
All Other, USD 1,819,330
Fiscal Year Total, USD 10,046,200

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Arie Belldegrun


David Chang


Joshua Kazam


Eric Schmidt


Alison Moore


David Bonderman

As Of  31 Dec 2018